Univariable and multivariable association between ETS status (with and without) and OS, PFS, TDD in HRQoL and PF for patients treated with atezolizumab from OAK and POPLAR
| ETS | Probability (%) at 24 months (95% CI) | Univariable analysis | Multivariable analysis* | |||||||
| N | HR (95% CI) | P value | c | N | HR (95% CI) | P value | c | |||
| OS | No | 23 (19 to 29) | 528 | – | <0.001 | 0.58 | 491 | – | <0.001 | 0.68 |
| Yes | 55 (44 to 69) | 135 | 0.33 (0.24 to 0.46) | 125 | 0.32 (0.23 to 0.45) | |||||
| PFS | No | 3 (2 to 6) | 528 | – | <0.001 | 0.60 | 491 | – | <0.001 | 0.66 |
| Yes | 31 (23 to 41) | 135 | 0.31 (0.25 to 0.39) | 125 | 0.31 (0.24 to 0.40) | |||||
| TDD in HRQoL | No | 10 (4 to 25) | 527 | – | 0.01 | 0.52 | 490 | – | 0.28 | 0.58 |
| Yes | 24 (15 to 37) | 134 | 0.73 (0.57 to 0.93) | 124 | 0.87 (0.66 to 1.13) | |||||
| TDD in PF | No | 23 (17 to 30) | 527 | – | <0.001 | 0.55 | 490 | – | <0.001 | 0.61 |
| Yes | 45 (36 to 57) | 134 | 0.52 (0.40 to 0.69) | 124 | 0.56 (0.41 to 0.75) | |||||
*Multivariable analysis adjusted for baseline ECOG PS, age, sex, race, smoking status, histology, count of prior treatments, PD-L1 expression, serum LDH levels and the presence of liver, lung or brain lesions.
ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality-of-life; LDH, lactate dehydrogenase; OS, overallsurvival; PD-L1, programmed death-ligand 1; PF, physical function; PFS, progression-free survival; TDD, time to deterioration.